Vertex announces UK approval for CASGEVY™
Congratulations to Vertex for their UK approval for CASGEVY™, a CRISPR/Cas9 gene-edited therapy, for...
read Details“Our sponsorship and workshop at the BMWS19 support our continued commitment to helping the global biopharmaceutical industry grow and evolve,” said Modality Solutions President Gary M. Hutchinson. “Today, more than ever, with complex regenerative medicine therapies, the biopharmaceutical industry is faced with the pressure to focus on the patient as they improve the quality, efficacy, and compliance of their life-saving products. It’s our mission to share our cold chain validation best practices that will help industry leaders understand the changing industry standards and how to integrate risk management processes with validation best practices to ensure compliance, quality, and product integrity.”
Modality Solutions will present “Cold Chain Validation Best Practices Including Immunotherapy” on Monday, November 11, at 2:35 p.m. PT in Breakout Room 3. During the session, attendees will take away valuable information including:
The Biomanufacturing World Summit brings together pharmaceutical executives, cutting-edge technology providers, and media partners for North America’s premier biologics event. The 2-day conference will focus on the patient as biopharmaceutical companies strive to improve the quality, efficacy, cost, and compliance of their life-saving products.
To view our BMWS19 sponsorship and presentation release, click here.
Congratulations to Vertex for their UK approval for CASGEVY™, a CRISPR/Cas9 gene-edited therapy, for...
read DetailsCongratulations to Melinta Therapeutics for their FDA Approval of REZZAYO™ for the Treatment of...
read DetailsCongratulations to Iveric Bio for their FDA approval for IZERVAY™️️, a new treatment for...
read Details